|Bid||5.45 x 0|
|Ask||5.55 x 0|
|Day's Range||5.08 - 5.65|
|52 Week Range||4.11 - 18.09|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug. 26, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Bed Bath & Beyond expands its Abacus Health Products CBDMEDIC distribution to over 1,000 locations across the United States.
Abacus' leading consumer brand, CBDMEDIC, includes a line of topical pain relief and skincare products. Abacus' leadership in the CBD market is underscored by its announcement that it has received purchase orders from approximately 7,000 retail locations representing 20 chains including the 3 largest national retail pharmacy chains. To schedule a one-on-one meeting with Abacus Health Products, you may submit your request online via the link provided upon registration or email your request to email@example.com.
Abacus Health Products, Inc. announces a voluntary extension to lock-up agreements representing approximately 8 million shares.
Abacus Health Products, Inc. (CSE: ABCS, OTCQX: ABAHF) (“Abacus” or the “Company”) reported its financial results today for the third quarter ended September 30, 2019. CBD CLINIC™ revenue increased 42.7% YoY, from $2.0 million to $2.9 million with sequential growth of 18.2% from Q2 2019. Total number of health care practitioners in the CBD CLINIC network grew from 12,000 to 14,500.
Abacus Health Products, Inc. (CSE: ABCS, OTCQX:ABAHF) (“Abacus” or the “Company”) today announced that it has received a purchase order from an additional major national pharmacy chain in the United States, which will be offering products from its CBDMEDIC product line. The chain will be adding three unique products from the CBDMEDIC product line to its shelves: Back & Neck Pain Relief Ointment, Active Sport™ Pain Relief Stick and Muscle & Joint Pain Relief Spray. With the addition of these locations the CBDMEDIC line of products will be available in over 20 retail chains and approximately 7,000 stores across the United States.
Abacus Health Products, Inc. will release its 2019 third quarter financial results on Thursday, November 21, 2019, prior to the market open and management will host a conference call at 10:00 AM Eastern Time to review the financial results.
Abacus Health Products, Inc. today announced that it will participate in the 2nd Annual Boston Cannabis Conference presented by Cowen.
IM Cannabis becomes third Israeli cannabis listing in past six weeks Toronto, Ontario--(Newsfile Corp. - November 5, 2019) - The Canadian Securities Exchange ("CSE" or "the Exchange") welcomes the listing of three Israel-based companies on the Exchange over the past six weeks: InnoCan Pharma Corp. (CSE: INNO), Isracann Biosciences Inc. (CSE: IPOT), and IM Cannabis Corp. (CSE: IMCC), which began trading today. ...
Abacus Health Products, Inc. (CSE: ABCS, OTCQX: ABAHF) (“Abacus” or the “Company”) today announced the expansion of the distribution capabilities of its CBD CLINIC product line through an agreement with WBC Group, LLC (“WBC”). WBC is one of the largest distributors of medical supplies to chiropractors, physical therapists, massage therapists and other health and wellness professionals in the United States. Under the agreement, which is effective November 1, 2019 for a term of 39 months, WBC, through its wholly owned subsidiary MeyerDCTM, will market and distribute CBD CLINIC products to its customers.
Abacus Health Products, Inc. (CSE: ABCS, OTCQX:ABAHF) (“Abacus” or the “Company”) today announced that an additional major national retail pharmacy chain in the United States will be offering products from its CBDMEDIC product line. The products are expected to launch into 1,300 of the chain’s retail locations across the United States. The chain will be adding three unique products from the CBDMEDIC product line to its shelves: Muscle & Joint Pain Relief Spray, Arthritis Aches & Pain Relief Ointment, and Back & Neck Pain Relief Ointment.
Abacus Health Products, Inc. (CSE: ABCS, OTCQX: ABAHF) (“Abacus” or the “Company”) today announced an agreement with Gillette Stadium and Patriot Place to promote awareness of its CBDMEDIC brand. This partnership further enhances the recently announced relationship between three-time champion Rob Gronkowski and Abacus. Gronkowski was one of the best and most recognized players during his nine-year professional football career and nowhere was he more popular than at home at Gillette Stadium and Patriot Place.
Abacus Health Products, Inc. (CSE: ABCS, OTCQX: ABAHF) (“Abacus” or the “Company”) today announced that it has received approval from the Depository Trust Company ("DTC") to make the Company's subordinate voting shares eligible to be electronically cleared and settled through DTC ("DTC Eligibility").
Abacus Health Products, Inc. (CSE: ABCS, OTCQX: ABAHF) (“Abacus” or the “Company”) today announced that it would be entering the convenience store market segment through an agreement with E&S International Enterprises, Inc. (“ESI”), for the distribution of CBDMEDIC™ products to this channel. ESI has a strong presence in the convenience store channel based on its leadership in the wholesale and distribution of consumer products. Abacus has developed new form factors of its leading topical pain relief and skincare product line, CBDMEDIC, as well as unique presentation platforms, specifically designed for the convenience store market.
Football star Rob Gronkowski is partnering with Abacus Health (ABAHF), a publicly traded CBD company listed in Canada, the maker of CBDMEDIC.
VANCOUVER , Aug. 27, 2019 /CNW/ - Trading resumes in: Company: Abacus Health Products Inc. CSE Symbol: ABCS (all issues) Resumption (ET): 10:30 AM IIROC can make a decision to impose a temporary suspension ...
VANCOUVER , Aug. 27, 2019 /CNW/ - The following issues have been halted by IIROC: Company: Abacus Health Products Inc. CSE Symbol: ABCS (All Issues) Reason: Pending News Halt Time (ET): 8:00:00 AM IIROC ...
WOONSOCKET, RI and TORONTO, July 31, 2019 /CNW/ - Abacus Health Products, Inc. ("Abacus" or the "Company") (CSE: ABCS) (OTCQX:ABAHF - News) is pleased to announce that Mr. Hannan Fleiman has joined its board of directors. Mr. Fleiman will also serve as Chair of the Company's Audit Committee and Corporate Governance, Nominating and Compensation Committee. With the addition of Mr. Fleiman, Abacus now has a total of five directors on its board. "I am pleased to welcome Hannan Fleiman to Abacus' board of directors," said Perry Antelman, CEO of Abacus.
WOONSOCKET, RI , July 17, 2019 /CNW/ - Abacus Health Products, Inc. (CSE: ABCS) (OTCQX: ABAHF) ("Abacus" or the "Company") today announced a new retail purchase order by Valu Merchandisers ...
WOONSOCKET, RI , July 11, 2019 /CNW/ - Abacus Health Products ("Abacus" or the "Company") (CSE: ABCS) today announced new retail purchase orders for its line of CBDMEDIC™ products, ...